HTL’s Executive Committee is composed of highly experienced professionals with international backgrounds.
Chief Executive Officer
Yvon Bastard has held the position of Chief Executive Officer at HTL Biotechnology since April 2017.
From 2008 to 2017, Mr. Bastard served as R&D Vice President of the Axyntis Group, a French CDMO in fine organic chemistry, involved in pharmaceutical and electronic APIs. In 2013, he became site manager for the main R&D and production site as well as CEO of the newly created JV Kyrapharm, which specialized in the purification of high-value materials by HPLC. During these 9 years, he participated in the acquisition process of two companies. From 1989 to 2008, Mr. Bastard contributed to the creation and growth of the Pharmaceutical Division of 3M Company. He set up new manufacturing processes for a new class of APIs, created new process development methodologies and was named Division Scientist. Yvon Bastard then became the technical referent for the Global Manufacturing Steering Committee and was responsible for process outsourcing programs worldwide. Across the Division, he also held responsibility for many multidisciplinary projects. Yvon Bastard holds a master's degree in Organic Chemistry from Rennes (ENSCR) and a degree in Molecular Chemistry from Rennes University.
Deputy Chief Executive Officer
Charles Ruban has been Deputy CEO of HTL since Sept 2019 and more specifically oversees Strategy, M&A, Marketing, Business Development, R&D and Innovation.
Mr. Ruban is a global executive in fast growing biotechnology and biopharmaceutical fields. At Stallergenes and DBV Technologies, he built up efficient organizations and delivered results in Supply Chain, Research & Development, Marketing and Global Management. He was instrumental in fundraising for a public company (including an IPO in the NASDAQ), and gained wide exposure to the investment community. He has in-depth experience in developing and launching new biological products, in Europe, the USA and Japan. Prior to this, Charles Ruban was a management and strategy consultant at Europgroup. He obtained a degree in Engineering from the Ecole Centrale de Lyon, trained at Harvard-MIT Division of Health Sciences and Technology for his Master of Science in Biomedical Engineering, and graduated with an Executive M.B.A. from INSEAD.
Chief Financial Officer
Susanne Liepmann joined HTL in May 2020 as Group CFO. She is responsible for all Finance, IT, Procurement and Legal matters.
Mrs. Liepmann has long-standing experience in Corporate Finance in various industries, including Private Equity-backed investments. She is most agile in multicultural contexts and her passion lies in organizational enablement of businesses through Finance. Mrs. Liepmann started her career as an external auditor at Arthur Andersen, one of the leading international professional firms and then joined ADP, an American BtoB Service company listed on the NASDAQ, where she held various corporate and field finance positions, lastly as CFO for France and Tunisia. Prior to joining HTL, she served as Group CFO at Ethypharm, a specialty pharmaceutical Group operating internationally. Susanne Liepmann holds a B.A. (Hons.) from NEOMA Business School (Reims, France), a German Diplom-Betriebswirt degree (Reutlingen, Germany), a Master in Finance (DESCF, France) and an Executive Master in Change degree from INSEAD.
Pascal Bordat joined the company in 2013 as Scientific Advisor to the CEO and is now in charge of the HTL Incubator.
Mr. Bordat has an extensive track record in the dermatological and cosmetic industry with leading positions in R&D and business development for 30 years. He is a named inventor on 23 patents, many of them in use on the market today. Pascal Bordat has a two-fold education background. He graduated from the Faculty of Pharmacy of Lyon as well as the Ecole Superieure de Chimie Industrielle de Lyon, he holds a doctorate from the University of Lyon in Pharmacochemistry and followed the INSEAD Management Program in 1997 (Euro-Asia Center).
Chief Scientific Officer
Anthony Bresin has held the position of Chief Scientific Officer at HTL since March 2018.
Mr. Bresin has more than 20 years experience in the industrial biotechnology domain, mainly in fermentation and purification with a specific focus on the scale-up from laboratory to industrial scale. From 2000 to 2018, he held several positions at ARD, a CRO company owned by Vivescia Industry and based in Pomacle, France. In his former position, he served as CSO of the company. He was appointed VP R&D at BioAmber from 2008 to 2010, a Joint-Venture company between ARD and DNP dedicated to the production of succinic acid by fermentation. From 2003 to 2009, he managed an ARD business unit dedicated to the production of polysaccharides by fermentation. From 2000 to 2009, Anthony Bresin was the R&D coordinator for hyaluronic acid at the ARD subsidiary Soliance (now part of the Givaudan group), responsible for production process improvement and hyaluronic acid applications. He is a named inventor on 10 patents (including 2 patents on hyaluronic acid for medical applications), 4 of which are used in the development of successful products on the market today. Anthony Bresin has a PhD in Industrial Fermentation on hyaluronic acid production from Reims Champagne Ardennes University.
Chief Industrial Performance Officer
Christophe Coyard was appointed Chief Industrial Performance Officer in April 2020. He leads Industrial projects, Engineering, EHS and Operational Excellence.
Mr. Coyard has more than 25 years of industrial experience gained in both automotive and pharmaceutical industries. He started his career as industrialization engineer for an automotive supplier, where he designed and launched equipment for a Japanese car manufacturer, before holding operational roles in manufacturing sites. As Technical and Method manager he developed his expertise in lean manufacturing management and engineering. Mr. Coyard joined the Pharmaceutical industry 15 years ago where he held Technical and Engineering Director roles on various GSK manufacturing sites. He acquired experience in industrial project management in a highly regulated environment.Christophe Coyard obtained an Engineering degree from the Ecole des Arts et Métier of Paris in 1994.
Chief Quality & Compliance Officer
Marie-Armelle Floc’h was appointed as Chief Quality and Compliance Officer of HTL in June 2019. She is in charge of Quality Assurance, Quality Control, compliance and regulatory topics.
Mrs. Floc’h has more than 24 years experience in Quality Control, Quality Assurance and project management in the pharmaceutical industry. From 2017 to 2019, Mrs. Floc’h held the position of Senior Quality Manager at GSK, a science-led global healthcare company. In this position, she was in charge of managing the Quality assurance and stability of polysaccharides vaccines. From 2001 to 2013, she held various executive positions at Ceva (pharmaceutical industry), such as Quality Control Manager or Project Management Leader. Marie-Armelle Floc’h has a degree in Chemical Engineering and a Master’s degree in Quality Assurance from Nantes University.
Chief Strategy and Transformation Officer
Bertrand Hurtault has held the position of Chief Strategy and Transformation Officer of HTL since August 2019.
Mr. Hurtault has served more than ten years as a consultant within KPMG Strategy Group where he actively participated in creating and developing the Healthcare and Life Sciences Strategy practice. As a principal, he mostly supported private equity firms in their investment strategy as well as over post-deal value creation programmes on both strategic and operational sides. He also led large lobbying projects for public institutions or union associations and supported several large companies in their IPO process. Mr. Hurtault started his career as a strategic and financial analyst at Varenne Capital Partners, a value investing oriented mutual fund. Bertrand Hurtault graduated from Paris-Assas University where he obtained a degree in Corporate and Market Finance, with a specialization in data analytics.
Chief Sales & Marketing Officer
Vincent Lajotte joined HTL in August 2019 to set up and lead the marketing and sales division.
From 2015 to 2019, Mr. Lajotte spent 5 years in Tereos, the French Global leader in Sugar and Sweeteners, where he established the Sales Excellence program including the European Sales-force reorganization before leading the Life Science and Nutrition Business group. From 1999 to 2015, Mr. Lajotte worked with Solvay (formerly Rhodia) where he held leadership positions in purchasing at a corporate level, supply chain and sales in Rare Earth and Silicas Industries, Marketing in Engineering Plastics and Business Unit Management in the Flavor and Fragrance market. Prior to this, from 1994 to 1999, he started his career in Logistics. Vincent Lajotte graduated from Neoma Business school in Rouen in 1992 and has followed various training programs at INSEAD.
Chief Operating Officer
Cyril Picault was appointed Chief Operating Officer of HTL in January 2018.
Mr. Picault served as Production Manager from October 2003 to January 2018. In the course of those 15 years, he contributed to the creation and growth of the Pharmaceutical Division of HTL. Mr. Picault set up manufacturing processes for a new API and was also in charge of maintenance and was responsible for the supply chain area. Cyril Picault holds a Master of Engineering from the APT (AgroParisTech) and trained at UCI (University of Irvine) in 2002.